Javascript must be enabled to continue!
Abstract 11752: Pitavastatin Treatment Ameliorates HIV-Nef Containing Extracellular Vesicle-Mediated Cardiomyocyte Dysfunction
View through CrossRef
Rationale:
The prevalence of cardiovascular diseases such as heart failure and left ventricular diastolic dysfunction remains high in People Living With HIV (PLWH) even with the advent of modern anti-retroviral therapy (ART). Sustained plasma persistence of the pro-inflammatory HIV protein Nef within extracellular vesicles (EV) of ART-treated patients may contribute to continued disease progression. We hypothesized that HIV-Nef induces cardiomyocyte dysfunction by elevating Reactive Oxygen Species (ROS) production which then increases apoptosis and senescence in cardiomyocytes.
Results:
Network analysis using
Metacore
of cytosolic and nuclear proteomics of human cardiomyocytes stimulated with HIV-Nef EV demonstrated changes in metabolic processes, DNA damage, oxidative stress and cytoskeletal remodeling. HIV-Nef EV promotes cardiomyocyte cellular dysfunction as evidenced by increased ROS production, DNA damage, apoptosis and premature senescence in both AC-16 cardiomyocyte cell line (n=5, p<0.001) and iPSC-derived cardiomyocytes (n=4, p<0.01). HIV-Nef EV stimulation induced cardiomyocyte metabolic switch by increasing consumption of anaerobic substrate (Lactic Acid) and decreasing consumption of TCA substrate (Citric Acid). [AE1] Network-science powered pathway analysis of HIV-Nef EV stimulated cardiomyocytes identified a key hub in Rac1-GTPase mediated pathways. Proteomic analysis of HIV-Nef transfected HEK293T cells indicated pitavastatin treatment altered Rac1 trafficking to inhibit interaction with HIV-Nef, suggesting a potential protective mechanism. Subsequently, cardiomyocyte dysfunction was abrogated by clinically relevant doses of pitavastatin (10-100nM ,n=4, p<0.01). Addition of HIV-Nef EV supernatant to AC-16 cardiomyocytes but not to those treated with pitavastatin increased chemotaxis of primary human macrophages (n=4, p<0.05).
Conclusion:
Pitavastatin treatment may prevent Nef EV-mediated cardiac dysfunction and inflammation in HIV patients. [AE1]I suggest including numbers of technical or biological replicates and p values when possible.
Ovid Technologies (Wolters Kluwer Health)
Title: Abstract 11752: Pitavastatin Treatment Ameliorates HIV-Nef Containing Extracellular Vesicle-Mediated Cardiomyocyte Dysfunction
Description:
Rationale:
The prevalence of cardiovascular diseases such as heart failure and left ventricular diastolic dysfunction remains high in People Living With HIV (PLWH) even with the advent of modern anti-retroviral therapy (ART).
Sustained plasma persistence of the pro-inflammatory HIV protein Nef within extracellular vesicles (EV) of ART-treated patients may contribute to continued disease progression.
We hypothesized that HIV-Nef induces cardiomyocyte dysfunction by elevating Reactive Oxygen Species (ROS) production which then increases apoptosis and senescence in cardiomyocytes.
Results:
Network analysis using
Metacore
of cytosolic and nuclear proteomics of human cardiomyocytes stimulated with HIV-Nef EV demonstrated changes in metabolic processes, DNA damage, oxidative stress and cytoskeletal remodeling.
HIV-Nef EV promotes cardiomyocyte cellular dysfunction as evidenced by increased ROS production, DNA damage, apoptosis and premature senescence in both AC-16 cardiomyocyte cell line (n=5, p<0.
001) and iPSC-derived cardiomyocytes (n=4, p<0.
01).
HIV-Nef EV stimulation induced cardiomyocyte metabolic switch by increasing consumption of anaerobic substrate (Lactic Acid) and decreasing consumption of TCA substrate (Citric Acid).
[AE1] Network-science powered pathway analysis of HIV-Nef EV stimulated cardiomyocytes identified a key hub in Rac1-GTPase mediated pathways.
Proteomic analysis of HIV-Nef transfected HEK293T cells indicated pitavastatin treatment altered Rac1 trafficking to inhibit interaction with HIV-Nef, suggesting a potential protective mechanism.
Subsequently, cardiomyocyte dysfunction was abrogated by clinically relevant doses of pitavastatin (10-100nM ,n=4, p<0.
01).
Addition of HIV-Nef EV supernatant to AC-16 cardiomyocytes but not to those treated with pitavastatin increased chemotaxis of primary human macrophages (n=4, p<0.
05).
Conclusion:
Pitavastatin treatment may prevent Nef EV-mediated cardiac dysfunction and inflammation in HIV patients.
[AE1]I suggest including numbers of technical or biological replicates and p values when possible.
Related Results
HIV WGS - 400bp Amplicon Tiling - Oxford Nanopore Technology Protocol v1
HIV WGS - 400bp Amplicon Tiling - Oxford Nanopore Technology Protocol v1
OSPHL in collaboration with APHL, will evaluate the performance of the Oxford Nanopore Technology sequencers for HIV genome sequencing using a modified protocol of the ARTIC amplic...
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract
Introduction
Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
Selective Inhibition of Receptor Pathways for Macrophage-Specific Cytokines by HIV-1 Nef Protein.
Selective Inhibition of Receptor Pathways for Macrophage-Specific Cytokines by HIV-1 Nef Protein.
Abstract
HIV-1 Nef protein is a well-known major determinant of the pathogenicity of the virus and much attention has been given to Nef to explain its contribution t...
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
A infecção pelo vírus do HIV pode ocorrer de diversas maneiras, tendo sua principal forma a via sexual por meio do sexo desprotegido. O vírus do HIV fica em um período de incubação...
Functional Analysis of HIV Type 1 Nef Reveals a Role for PAK2 as a Regulator of Cell Phenotype and Function in the Murine Dendritic Cell Line, DC2.4
Functional Analysis of HIV Type 1 Nef Reveals a Role for PAK2 as a Regulator of Cell Phenotype and Function in the Murine Dendritic Cell Line, DC2.4
Abstract
The HIV-1 Nef protein plays a critical role in viral pathogenesis. Nef has been shown to modulate dendritic cell (DC) function, in particular perturbing ...
The Role of ERK1/2 Signaling Pathway in Nef Protein Upregulation of the Expression of the Intercellular Adhesion Molecule 1 in Endothelial Cells
The Role of ERK1/2 Signaling Pathway in Nef Protein Upregulation of the Expression of the Intercellular Adhesion Molecule 1 in Endothelial Cells
Human immunodeficiency virus (HIV)-infected patients have increased rates of atherosclerotic cardiovascular diseases because the highly active antiretroviral therapy (HAART) decrea...
North East Frigg Development and Experience
North East Frigg Development and Experience
Summary
The North East Frigg (NEF) gas field is a small satellite of the Frigg field; in terms of recoverable reserves as estimated at the beginning of the projec...
La protéine Nef du VIH-1 : Contribution des complexes adaptateurs de la voie d'endocytose aux fonctions de Nef
La protéine Nef du VIH-1 : Contribution des complexes adaptateurs de la voie d'endocytose aux fonctions de Nef
La protéine Nef des virus de l’immunodéficience humaine (VIH-1 et VIH-2) joue un rôle essentiel dans la physiopathologie de l’infection et induction du SIDA. La capacité de Nef à p...

